Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/19884547/ below:

Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening

Review

Affiliations

• ¹ Epidemiology and Biostatistics Cluster, International Agency for Research on Cancer, Lyon, France. pre@iarc.fr

• PMID: 19884547
• DOI: 10.1200/JCO.2009.22.7041

Item in Clipboard

Review

Philippe Autier et al. J Clin Oncol. 2009.

• ¹ Epidemiology and Biostatistics Cluster, International Agency for Research on Cancer, Lyon, France. pre@iarc.fr

• PMID: 19884547
• DOI: 10.1200/JCO.2009.22.7041

Item in Clipboard

Purpose: We assessed changes in advanced cancer incidence and cancer mortality in eight randomized trials of breast cancer screening.

Patients and methods: Depending on published data, advanced cancer was defined as cancer > or = 20 mm in size (four trials), stage II+ (four trials), and > or = one positive lymph node (one trial). For each trial, we obtained the estimated relative risk (RR) and 95% CI between the intervention and control groups, for both breast cancer mortality and diagnosis of advanced breast cancer. Using a meta-regression approach, log(RR-mortality) was regressed on log(RR-advanced cancer), weighting each trial by the reciprocal of the square of the standard error of log(RR) for mortality.

Results: RR for advanced breast cancer ranged from 0.69 (95% CI, 0.61 to 0.78) in the Swedish Two-County Trial to 0.97 (95% CI, 0.97 to 1.25) in the Canadian National Breast Screening Study-1 (NBSS-1) trial. Log(RR)s for advanced cancer were highly predictive of log(RR)s for mortality (R(2) = 0.95; P < .0001), and the linear regression curve had a slope of 1.00 (95% CI, 0.76 to 1.25) after fixing the intercept to zero. The slope changed only slightly after excluding the Two-County Trial and the Canadian NBSS-1 and NBSS-2 trials.

Conclusion: In trials on breast cancer screening, for each unit decrease in incidence of advanced breast cancer, there was an equal decrease in breast cancer mortality. Monitoring of incidence of advanced breast cancer may provide information on the current impact of screening on breast cancer mortality in the general population.

PubMed Disclaimer

• The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study.

  Tarone RE. Tarone RE. Cancer. 1995 Feb 15;75(4):997-1003. doi: 10.1002/1097-0142(19950215)75:4<997::aid-cncr2820750415>3.0.co;2-m. Cancer. 1995. PMID: 7842421

• Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.

  Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Shen Y, et al. J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203. doi: 10.1093/jnci/dji239. J Natl Cancer Inst. 2005. PMID: 16106024

• Long-term effects of mammography screening: updated overview of the Swedish randomised trials.

  Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Nyström L, et al. Lancet. 2002 Mar 16;359(9310):909-19. doi: 10.1016/S0140-6736(02)08020-0. Lancet. 2002. PMID: 11918907 Review.

• Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening.

  Chiu SY, Duffy S, Yen AM, Tabár L, Smith RA, Chen HH. Chiu SY, et al. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1219-28. doi: 10.1158/1055-9965.EPI-09-1028. Epub 2010 Apr 20. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20406961 Clinical Trial.

• Mammography in symptomatic and asymptomatic patients.

  Stomper PC, Gelman RS. Stomper PC, et al. Hematol Oncol Clin North Am. 1989 Dec;3(4):611-40. Hematol Oncol Clin North Am. 1989. PMID: 2691492 Review.

• Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrollees.

  Fenton JJ, Xing G, Elmore JG, Bang H, Chen SL, Lindfors KK, Baldwin LM. Fenton JJ, et al. Ann Intern Med. 2013 Apr 16;158(8):580-7. doi: 10.7326/0003-4819-158-8-201304160-00002. Ann Intern Med. 2013. PMID: 23588746 Free PMC article.

• Outcomes of surveillance for contralateral breast cancer in patients less than age 60 at the time of initial diagnosis.

  Weinstock C, Bigenwald R, Hochman T, Sun P, Narod SA, Warner E. Weinstock C, et al. Curr Oncol. 2012 Jun;19(3):e160-4. doi: 10.3747/co.19.890. Curr Oncol. 2012. PMID: 22670105 Free PMC article.

• Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.

  Kerlikowske K, Chen S, Golmakani MK, Sprague BL, Tice JA, Tosteson ANA, Rauscher GH, Henderson LM, Buist DSM, Lee JM, Gard CC, Miglioretti DL. Kerlikowske K, et al. J Natl Cancer Inst. 2022 May 9;114(5):676-685. doi: 10.1093/jnci/djac008. J Natl Cancer Inst. 2022. PMID: 35026019 Free PMC article.

• MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer.

  Li XY, Luo QF, Wei CK, Li DF, Li J, Fang L. Li XY, et al. Int J Clin Exp Med. 2014 Jan 15;7(1):32-40. eCollection 2014. Int J Clin Exp Med. 2014. PMID: 24482686 Free PMC article.

• The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.

  Birnbaum J, Gadi VK, Markowitz E, Etzioni R. Birnbaum J, et al. Ann Intern Med. 2016 Feb 16;164(4):236-43. doi: 10.7326/M15-0754. Epub 2016 Jan 12. Ann Intern Med. 2016. PMID: 26756332 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3